Explore BWIN stock price, technical analysis, earnings, analyst ratings, and valuation for The Baldwin Insurance Group. Is BWIN stock a buy? Get balanced insights as of February 28, 2026.
Introduction
BWIN stock tracks The Baldwin Insurance Group, Inc., a firm offering risk management, insurance brokerage, and employee benefits solutions to businesses and individuals. Investors watch BWIN closely amid volatile insurance markets and recent earnings beats. Broader conditions like rising interest rates and economic uncertainty impact financial services stocks like BWIN.
Latest Stock Price & Trend
BWIN stock closed at around $23.50 in recent trading, reflecting a sharp 22% jump on better-than-expected earnings news. The one-day performance showed volatility, with shares gapping up after positive reports. Over five days, it gained modestly amid sector rotation.
The one-month trend fell 18.52%, signaling pullback pressure. Three-month performance declined amid broader market dips. Six-month returns stayed mixed, while year-to-date, BWIN dropped about 22% versus last year.
The 52-week high hit $55.82, and the low was $22.15. Overall, the trend leans bearish short-term but with bullish momentum from earnings, suggesting caution for investors until stabilization.
Technical Analysis
Support levels sit near $22.15, the 52-week low, where buyers may step in. Resistance looms at $27-31, recent highs blocking upside.
RSI at 45-52 indicates neutral territory, neither overbought nor oversold – a balanced momentum gauge. MACD shows a sell signal at -0.13, pointing to weakening short-term trend.
The 50-day moving average hovers around $24.94, above current price for a sell bias; 200-day average suggests longer-term pressure. No golden cross appears; it’s below both averages, hinting at bearish control. Trading volume spiked recently to 621k shares versus 902k average, showing heightened interest.
Analyst Ratings & Price Targets
Eight analysts rate BWIN as Buy overall. Breakdown includes buys, holds; average target $38.43, high $49, low $25 – implying 61% upside.
Wells Fargo cut target to $21 from $27, equal weight. Consensus leans positive, signaling growth potential for investors.
Insider Activity
Insiders sold $10.9M in shares over last three months, no major buys noted. This trend implies caution from management amid stock declines.
Large sales dominate, suggesting profit-taking rather than deep concern.
Valuation Analysis
Trailing P/E unavailable due to negative EPS of -0.27. Forward P/E at 16.72 looks reasonable.
Price-to-sales forward at 0.91 undervalues versus peers’ 5.74 average. Revenue grew 10% organically YoY to $1.46B TTM; EPS growth mixed.
Free cash flow rose 6% to $26M recently; debt position manageable with current ratio 1.15. Compared to peers like Marsh & McLennan, BWIN appears undervalued on sales growth.
Recent Earnings & Catalysts
Q4 2025 EPS met $0.27 estimate; revenue $323M missed slightly by 1.22%. Prior quarter beat revenue 2.58% at $336M, EPS $0.33 versus $0.34 expected.
Guidance shows adjusted EBITDA up 12% to $113.8M, margin 27.5%. Catalysts include organic growth and brokerage expansions; earnings drove 22% stock surge.
Bullish Case
Revenue growth at 10% YoY stems from strong demand in risk management. Tech-driven solutions boost margins.
Organic expansion and client wins support steady gains. Operational tweaks lifted EBITDA 12%.
Bearish Case
Competition from giants pressures margins. Negative net income -$17.76M signals profitability risks.
Economic slowdowns could spur customer churn; regulatory changes loom in insurance.
Market Sentiment & Investor Psychology
Short interest data limited, but options show balanced calls/puts. Institutional ownership steady at high levels.
Retail buying spiked post-earnings. Sentiment tilts neutral to optimistic on growth, despite bearish technicals.
Short-Term Outlook
Technicals show sell MACD and below averages, but volume uptick aids. Momentum from earnings suggests sideways to mild upside next weeks, barring market shocks.
Medium to Long-Term Outlook
Solid brokerage model thrives in growing insurance sector. Financials improve with 10% revenue pace.
Competitive edge in specialty lines; hold for long-term investors eyeing recovery.
FAQ
Is BWIN stock a buy right now? Analysts say Buy with $38 target, but watch bearish trends.
What is the price target for BWIN stock? Average $38.43, range $25-49.
What are major risks for BWIN stock? Insider selling, negative EPS, competition.
What is BWIN earnings outlook? Next report Aug 2025; recent beats on revenue.
BWIN forecast long term? Positive on growth, undervalued metrics.
Suggestions
Compare with Opendoor stock analysis.
See our Aon stock forecast.
Read insurance sector valuation breakdown.
Final Balanced Conclusion
Hold BWIN stock. Growth drivers offset near-term weakness; undervalued but monitor earnings.
Disclaimer: This article is for informational purposes only and not financial advice.